■ Ingredients found in HepAssure are substances (metabolites) involved in normal human metabolism.
■ Chronic Liver Disease (CLD) alters or up-regulates certain metabolic pathways in Patients with CLD.
■ HepAssure provides metabolites that are affected by these CLD-altered metabolic pathways.
■ Studies show that patients with Chronic Liver Disease (CLD) require more of these metabolites in their diet than normal healthy people.
■ HepAssure Medical Food for Patients with CLD is designed provide metabolites in order to satisfy the distinctive nutritional requirements of patients with CLD.
HepAssure is not yet commercially available, HOWEVER, HepAssure and HonorHealth are currently enrolling patients in a Human Clinical Trial for Patients with NASH in cirrhosis.
The HonorHealth IRB-approved Human Clinical Trial was approved in the fall of 2016. We are currently enrolling qualified patients in this Phase 2 Human Clinical Trial.
In order to qualify the patient must have stage 4 liver fibrosis (cirrhosis) by NASH, as verified by fibroscan.
If you are interested in applying for enrollment in the human clinical trial please call The LiverLab at 844-254-8375 (toll free) or go to TheLiverLab.com
Use the links on this page to find out more about HepAssure